The aim of the present study is to report on the ability of metabolic tumor volume (MTV) of liver metastases from pre-transplant18F-FDG PET/CT in combination with conventional radiological measurements from CT scans to predict long-term disease-free survival (DFS), overall survival (OS), and survival after relapse (SAR) after liver transplantation for colorectal liver metastases. The total liver MTV was obtained from the18F-FDG PET/CT, and the size of the largest metastasis and the total number of metastases were obtained from the CT. DFS, OS, and SAR for patients with a low and high MTV, in combination with a low and high size, number, and tumor burden score, were compared using the Kaplan–Meier method and log–rank test. Patients with a low number of metastases and low MTV had a significantly longer OS than those with a high MTV, with a median survival of 151 vs. 26 months (p= 0.010). Patients with a high number of metastases and low MTV had significantly longer DFS, OS, and SAR than patients with a high MTV (p= 0.034, 0.006, and 0.026). The tumor burden score of group/zone 3, in combination with a low MTV, had a significantly improved DFS, OS, and SAR compared to those with a high MTV (p= 0.034, <0.001, and 0.006). Patients with a low MTV of liver metastases had a long DFS, OS, and SAR despite a high number of liver metastases and a high tumor burden score.
本研究旨在探讨肝转移瘤代谢肿瘤体积（MTV）结合传统CT影像学测量指标，在预测结直肠癌肝转移患者肝移植术后长期无病生存期（DFS）、总生存期（OS）及复发后生存期（SAR）中的预测价值。通过18F-FDG PET/CT获取肝脏总MTV，通过CT扫描获取最大转移灶尺寸及转移灶总数。采用Kaplan-Meier法与对数秩检验，比较低/高MTV联合低/高转移灶尺寸、数量及肿瘤负荷评分患者的DFS、OS及SAR差异。结果显示：低转移灶数量联合低MTV患者的中位OS显著优于高MTV患者（151个月 vs 26个月，p=0.010）；高转移灶数量联合低MTV患者的DFS、OS及SAR均显著优于高MTV患者（p值分别为0.034、0.006、0.026）；肿瘤负荷评分3区/组联合低MTV患者的DFS、OS及SAR较之高MTV患者显著改善（p值分别为0.034、<0.001、0.006）。研究表明，即使存在高数量肝转移灶或高肿瘤负荷评分，低MTV患者仍能获得较长的DFS、OS及SAR。
肿瘤(癌症)患者之家